Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Regeneron settles patent lawsuit over protein for testing COVID-19 treatments December 16, 2024 AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Regeneron Pharmaceuticals ... or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

It is the first FDA-approved treatment ... at Regeneron, said the application of those technologies “to address the Ebola outbreak laid the foundation for” the company’s COVID-19 efforts.

to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. Regeneron and ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

In a small study, patients with the syndrome were more likely to experience reactivation of Epstein-Barr virus and high ...

A new study shows non-menopausal women between the ages of 40 and 54 had a significantly higher risk of developing long covid ...

A Chinese biotech that became popular by co-developing an anti-Covid drug has filed for a Hong Kong stock market listing.